Point72 Asset Management
NGM

Point72 Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Point72 Asset Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,116
Closed -$94.3K – 2921
2023
Q1 		$94.3K Buy
+23,116
New +$107K ﹤0.01% 1644
2022
Q4 		– Sell
-362,900
Closed -$4.75M – 1865
2022
Q3 		$4.75M Sell
362,900
-957,762
-73% -$14.5M 0.02% 742
2022
Q2 		$16.9M Sell
1,320,662
-1,890,209
-59% -$26.2M 0.07% 356
2022
Q1 		$49M Sell
3,210,871
-87,027
-3% -$1.36M 0.19% 149
2021
Q4 		$58.4M Buy
3,297,898
+1,854,904
+129% +$35.6M 0.23% 107
2021
Q3 		$30.3M Buy
1,442,994
+578,794
+67% +$12.7M 0.13% 209
2021
Q2 		$17M Sell
864,200
-1,310,800
-60% -$30.7M 0.08% 323
2021
Q1 		$63.2M Buy
2,175,000
+413,843
+23% +$11.6M 0.3% 76
2020
Q4 		$53.4M Buy
1,761,157
+149,307
+9% +$3.27M 0.26% 85
2020
Q3 		$25.6M Buy
1,611,850
+88,265
+6% +$1.61M 0.13% 215
2020
Q2 		$30.1M Buy
1,523,585
+527,290
+53% +$10.1M 0.2% 147
2020
Q1 		$12.3M Buy
+996,295
New +$16.3M 0.1% 283

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Point72 Asset Management's NGM Position: Q2 2023 in Review

Point72 Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 23,116 shares — an estimated $94.3K sold.

Point72 Asset Management first reported a position in NGM in Q1 2020 and held it in 12 quarters. The position peaked at $63.2M in Q1 2021. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

  • Point72 Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Point72 Asset Management sold 23,116 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $94.3K.
  • Point72 Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
  • Point72 Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $63.2M in Q1 2021.
  • 106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.